Literature DB >> 29614136

The Evolving Landscape of Psoriasis Treatment.

April W Armstrong1, Kenneth B Gordon2, M Alan Menter3, Jashin J Wu4.   

Abstract

The process of discovering new drugs for plaque psoriasis has revealed much about the multisystemic nature of the disease. Current and emerging biologic agents may reliably achieve a Psoriasis Area and Severity Index (PASI 75) up to 90. Initially, clinicians select therapies based on the severity of the psoriasis. Although mild disease can be treated with topical agents, for patients with moderate to severe disease, concurrent therapy with oral systemic agents, biologics, and/ or phototherapy needs to be considered. In some instances, clinicians may need to combine medications to provide patients with rapid relief of symptoms. Semin Cutan Med Surg 37(supp2):S39-S43. 2018 published by Frontline Medical Communications.

Entities:  

Keywords:  Biologics; phototherapy; psoriasis pathophysiology; systemic oral therapy; topical therapy

Mesh:

Substances:

Year:  2018        PMID: 29614136     DOI: 10.12788/j.sder.2018.009

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  3 in total

1.  Effectiveness comparisons of acupuncture for psoriasis: A Bayesian network meta-analysis protocol.

Authors:  Zhi-Yin Xie; Yu Zhou; Sheng Deng; Wei Ding; Xing-Wu Duan; Li-Rong Yang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

2.  Effectiveness comparisons of traditional Chinese medicine for psoriasis: A Bayesian network meta-analysis.

Authors:  Longjun Wang; Yun Tao; Sheng Deng; Liyuan Chu; Linge Li
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.

Authors:  Mark G Lebwohl; Andrew Blauvelt; Alan Menter; Kim A Papp; Scott Guenthner; Radhakrishnan Pillai; Robert J Israel; Abby Jacobson
Journal:  Am J Clin Dermatol       Date:  2019-12       Impact factor: 7.403

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.